Mathew et al. showed that administration of the JAK1 inhibitor itacitinib after ICI therapy with the anti-PD-1 antibody pembrolizumab improved immune function and antitumor response in mice and also resulted in high response rates in a phase 2 clinical trial for metastatic NSCLC. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.